microdosing glp 1 agonists GLP-1 Microdosing GLP-1s: Does It Work?
Description
These analogs are eight times more potent than endogenous GLP-1 (114)
If adult approval proceeds as expected, pediatric trials would likely follow within 2-3 years, focusing initially on adolescents aged 12-17 with BMI at or above the 95th percentile
A lower mortality in the GLP-1 RA group would expectedly lead to an underestimation of the fracture risk in that group, thereby exaggerating a protective effect of GLP-1 RAs
J Neurol Neurosurg Psychiatry 89:10881100
